Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats

World Journal of Gastroenterology

Volumn 20, Issue 10, 2014, Pages 2653-2663

  Tanaka, Kosuke ^a   Masaki, Yuko ^a   Tanaka, Masatake ^a   Miyazaki, Masayuki ^a   Enjoji, Munechika ^b   Nakamuta, Makoto ^c   Kato, Masaki ^a   Nomura, Masatoshi ^a   Inoguchi, Toyoshi ^d   Kotoh, Kazuhiro ^a   Takayanagi, Ryoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

Adipose tissue; Energy expenditure; Exenatide; Glucagon like peptide 1; Hepatic steatosis; Lipolysis; Nonalcoholic fatty liver disease

Indexed keywords

ACYL COENZYME A OXIDASE; CARNITINE PALMITOYLTRANSFERASE I; CATALASE; EXENDIN 4; LONG CHAIN ACYL COENZYME A DEHYDROGENASE; MANGANESE SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL LIPASE; GLUCOSE BLOOD LEVEL; PEPTIDE; VENOM;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALORIC INTAKE; CALORIMETRY; CONTROLLED STUDY; FATTY ACID OXIDATION; FATTY LIVER; GENE EXPRESSION; GLUCOSE TOLERANCE TEST; HISTOLOGY; HYDROLYSIS; IMMUNOBLOTTING; LIPID METABOLISM; LIPID STORAGE; MALE; NONHUMAN; OXYGEN CONSUMPTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WEIGHT GAIN; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; ENERGY METABOLISM; FOOD INTAKE; GENE EXPRESSION REGULATION; GENETICS; GLUCOSE BLOOD LEVEL; LIPID DIET; LIPOLYSIS; LIVER; METABOLISM; MITOCHONDRION; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; SKELETAL MUSCLE; TIME; WISTAR RAT;

ADIPOSE TISSUE; ANIMALS; APPETITE REGULATION; BLOOD GLUCOSE; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ENERGY INTAKE; ENERGY METABOLISM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; LIPOLYSIS; LIVER; MALE; MITOCHONDRIA; MUSCLE, SKELETAL; NON-ALCOHOLIC FATTY LIVER DISEASE; OXYGEN CONSUMPTION; PEPTIDES; RATS, WISTAR; TIME FACTORS; UP-REGULATION; VENOMS; WEIGHT GAIN;

EID: 84896830766     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i10.2653     Document Type: Article

References (47)

1. Page J. Nonalcoholic fatty liver disease: the hepatic metabolic syndrome. J Am Acad Nurse Pract 2012; 24: 345-351 [PMID: 22672485 DOI: 10.1111/j.1745-7599.2012.00716.x]
2. Paredes AH, Torres DM, Harrison SA. Nonalcoholic fatty liver disease. Clin Liver Dis 2012; 16: 397-419 [PMID: 22541706 DOI: 10.1016/j.cld.2012.03.005]
3. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012; 32: 3-13 [PMID: 22418883 DOI: 10.1055/ s-0032-1306421]
4. Brunt EM. Pathology of nonalcoholic steatohepatitis. Hepatol Res 2005; 33: 68-71 [PMID: 16214395]
5. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011; 46 Suppl 1: 63-69 [PMID: 20844903 DOI: 10.1007/s00535-010-0311-8]
6. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012; 10: 1342-1359. e2 [PMID: 23041539 DOI: 10.1016/ j.cgh.2012.10.001]
7. Yki-Järvinen H. Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data. Curr Opin Clin Nutr Metab Care 2010; 13: 709-714 [PMID: 20842026 DOI: 10.1097/MCO.0b013e32833f4b34]
8. Khan R, Foster GR, Chowdhury TA. Managing diabetes in patients with chronic liver disease. Postgrad Med 2012; 124: 130-137 [PMID: 22913901 DOI: 10.3810/pgm.2012.07.2574]
9. Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006; 82: 315-322 [PMID: 16679470]
10. Russell S. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Int J Clin Pharm 2013; 35: 159-172 [PMID: 23263796 DOI: 10.1007/s11096-012-9729-9]
11. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004; 117: 77-88 [PMID: 14700743]
12. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157 [PMID: 17498508]
13. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagonlike peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987; 79: 616-619 [PMID: 3543057]
14. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402-7405 [PMID: 1313797]
15. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993; 268: 19650-19655 [PMID: 8396143]
16. Gallwitz B. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. Int J Clin Pract 2006; 60: 1654-1661 [PMID: 17109672]
17. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439 [PMID: 17928588]
18. Dailey MJ, Moran TH. Glucagon-like peptide 1 and appetite. Trends Endocrinol Metab 2013; 24: 85-91 [PMID: 23332584 DOI: 10.1016/j.tem.2012.11.008]
19. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD, Parkes DG, Young AA. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulinresistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005; 146: 2069-2076 [PMID: 15618356]
20. Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C, Faraci G, Pacetti D, Vivarelli M, Nicolini D, Garelli P, Casini A, Manco M, Mingrone G, Risaliti A, Frega GN, Benedetti A, Gastaldelli A. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 2011; 31: 1285-1297 [PMID: 21745271 DOI: 10.1111/j.1478-3231.2011.02462.x]
21. Mells JE, Fu PP, Sharma S, Olson D, Cheng L, Handy JA, Saxena NK, Sorescu D, Anania FA. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol 2012; 302: G225-G235 [PMID: 22038829 DOI: 10.1152/ajpgi.00274.2011]
22. Lee J, Hong SW, Chae SW, Kim DH, Choi JH, Bae JC, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Kim SW, Lee WY. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PLoS One 2012; 7: e31394 [PMID: 22363635 DOI: 10.1371/journal. pone.0031394]
23. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006; 43: 173-181 [PMID: 16374859]
24. Mérida E, Delgado E, Molina LM, Villanueva-Peñacarrillo ML, Valverde I. Presence of glucagon and glucagon-like peptide-1-(7-36)amide receptors in solubilized membranes of human adipose tissue. J Clin Endocrinol Metab 1993; 77: 1654-1657 [PMID: 8263154]
25. Jolly SR, Kane WJ, Bailie MB, Abrams GD, Lucchesi BR. Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase. Circ Res 1984; 54: 277-285 [PMID: 6697450]
26. Matés JM, Pérez-Gómez C, Núñez de Castro I. Antioxidant enzymes and human diseases. Clin Biochem 1999; 32: 595-603 [PMID: 10638941]
27. Orr WC, Sohal RS. Extension of life-span by overexpression of superoxide dismutase and catalase in Drosophila melanogaster. Science 1994; 263: 1128-1130 [PMID: 8108730]
28. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17: 4-12 [PMID: 16613757]
29. Aldhahi W, Hamdy O. Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep 2003; 3: 293-298 [PMID: 12866991]
30. Lee YS, Park MS, Choung JS, Kim SS, Oh HH, Choi CS, Ha SY, Kang Y, Kim Y, Jun HS. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia 2012; 55: 2456-2468 [PMID: 22722451 DOI: 10.1007/s00125-012-2592-3]
31. Bereiter-Hahn J, Vöth M. Dynamics of mitochondria in living cells: shape changes, dislocations, fusion, and fission of mitochondria. Microsc Res Tech 1994; 27: 198-219 [PMID: 8204911]
32. Chan DC. Mitochondrial fusion and fission in mammals. Annu Rev Cell Dev Biol 2006; 22: 79-99 [PMID: 16704336]
33. Kita T, Nishida H, Shibata H, Niimi S, Higuti T, Arakaki N. Possible role of mitochondrial remodelling on cellular triacylglycerol accumulation. J Biochem 2009; 146: 787-796 [PMID: 19671539 DOI: 10.1093/jb/mvp124]
34. Bijland S, Mancini SJ, Salt IP. Role of AMP-activated protein kinase in adipose tissue metabolism and inflammation. Clin Sci (Lond) 2013; 124: 491-507 [PMID: 23298225 DOI: 10.1042/ CS20120536]
35. Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010; 51: 1584-1592 [PMID: 20225248 DOI: 10.1002/hep.23569]
36. Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, Barzilai N, Oren R, Fishman S. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMPactivated protein kinase. J Hepatol 2011; 54: 1214-1223 [PMID: 21145820 DOI: 10.1016/j.jhep.2010.09.032]
37. Gaetani GF, Ferraris AM, Rolfo M, Mangerini R, Arena S, Kirkman HN. Predominant role of catalase in the disposal of hydrogen peroxide within human erythrocytes. Blood 1996; 87: 1595-1599 [PMID: 8608252]
38. Miriyala S, Holley AK, St Clair DK. Mitochondrial superoxide dismutase--signals of distinction. Anticancer Agents Med Chem 2011; 11: 181-190 [PMID: 21355846]
39. Zorzano A, Liesa M, Palacín M. Role of mitochondrial dynamics proteins in the pathophysiology of obesity and type 2 diabetes. Int J Biochem Cell Biol 2009; 41: 1846-1854 [PMID: 19703653 DOI: 10.1016/j.biocel.2009.02.004]
40. Civitarese AE, Ravussin E. Mitochondrial energetics and insulin resistance. Endocrinology 2008; 149: 950-954 [PMID: 18202132]
41. Montrose-Rafizadeh C, Yang H, Wang Y, Roth J, Montrose MH, Adams LG. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. J Cell Physiol 1997; 172: 275-283 [PMID: 9284947]
42. Vendrell J, El Bekay R, Peral B, García-Fuentes E, Megia A, Macias-Gonzalez M, Fernández Real J, Jimenez-Gomez Y, Escoté X, Pachón G, Simó R, Selva DM, Malagón MM, Tinahones FJ. Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology 2011; 152: 4072-4079 [PMID: 21862620 DOI: 10.1210/ en.2011-1070]
43. Boschmann M, Engeli S, Dobberstein K, Budziarek P, Strauss A, Boehnke J, Sweep FC, Luft FC, He Y, Foley JE, Jordan J. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab 2009; 94: 846-852 [PMID: 19088168 DOI: 10.1210/jc.2008-1400]
44. Nogueiras R, Pérez-Tilve D, Veyrat-Durebex C, Morgan DA, Varela L, Haynes WG, Patterson JT, Disse E, Pfluger PT, López M, Woods SC, DiMarchi R, Diéguez C, Rahmouni K, Rohner-Jeanrenaud F, Tschöp MH. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci 2009; 29: 5916-5925 [PMID: 19420258 DOI: 10.1523/JNEUROSCI.5977-08.2009]
45. Carmen GY, Víctor SM. Signalling mechanisms regulating lipolysis. Cell Signal 2006; 18: 401-408 [PMID: 16182514]
46. Bartness TJ, Song CK. Thematic review series: adipocyte biology. Sympathetic and sensory innervation of white adipose tissue. J Lipid Res 2007; 48: 1655-1672 [PMID: 17460327]
47. Lockie SH, Heppner KM, Chaudhary N, Chabenne JR, Morgan DA, Veyrat-Durebex C, Ananthakrishnan G, Rohner-Jeanrenaud F, Drucker DJ, DiMarchi R, Rahmouni K, Oldfield BJ, Tschöp MH, Perez-Tilve D. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes 2012; 61: 2753-2762 [PMID: 22933116]